Clinical Trial Update: Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet. [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study comparing two formulations of a 4 mg risperidone tablet has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• RISPERIDONE (RISPERIDONE)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia, Schizoaffective Disorders | Phase 1 | Status: COMPLETED